Nantahala Capital Management LLC Takes Position in TriSalus Life Sciences, Inc. $TLSI

Nantahala Capital Management LLC bought a new stake in shares of TriSalus Life Sciences, Inc. (NASDAQ:TLSI) in the second quarter, HoldingsChannel.com reports. The institutional investor bought 1,000,000 shares of the company’s stock, valued at approximately $4,550,000.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the business. JPMorgan Chase & Co. lifted its stake in shares of TriSalus Life Sciences by 35,804.8% in the 2nd quarter. JPMorgan Chase & Co. now owns 7,540 shares of the company’s stock valued at $41,000 after purchasing an additional 7,519 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. purchased a new stake in TriSalus Life Sciences in the second quarter worth $47,000. Cura Wealth Advisors LLC purchased a new stake in TriSalus Life Sciences in the second quarter worth $36,000. Invesco Ltd. bought a new position in TriSalus Life Sciences in the fourth quarter worth $72,000. Finally, Abel Hall LLC bought a new position in TriSalus Life Sciences in the fourth quarter worth $73,000. Hedge funds and other institutional investors own 2.58% of the company’s stock.

Wall Street Analysts Forecast Growth

TLSI has been the subject of a number of recent research reports. Wall Street Zen raised shares of TriSalus Life Sciences from a “sell” rating to a “hold” rating in a research report on Sunday, August 23rd. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of TriSalus Life Sciences in a research note on Friday, August 7th. Finally, Lake Street Capital lowered their target price on shares of TriSalus Life Sciences from $10.00 to $8.00 and set a “buy” rating for the company in a report on Wednesday, May 13th. Two analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, TriSalus Life Sciences presently has a consensus rating of “Hold” and a consensus price target of $7.50.

TriSalus Life Sciences Price Performance

TLSI opened at $4.83 on Friday. The company’s 50-day simple moving average is $4.66 and its two-hundred day simple moving average is $4.32. The company has a debt-to-equity ratio of 5.05, a quick ratio of 4.97 and a current ratio of 5.35. The stock has a market capitalization of $297.43 million, a P/E ratio of -3.72 and a beta of 0.43. TriSalus Life Sciences, Inc. has a 52-week low of $2.20 and a 52-week high of $7.95.

TriSalus Life Sciences (NASDAQ:TLSI) last posted its quarterly earnings data on Thursday, August 6th. The company reported ($0.16) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.16). The business had revenue of $11.41 million during the quarter, compared to analysts’ expectations of $10.27 million.

TriSalus Life Sciences Company Profile

TriSalus Life Sciences, Inc is a clinical-stage biotechnology company focused on the development and commercialization of non-invasive drug–device combination therapies for oncology applications. Leveraging proprietary electroporation and ultrasound platforms, the company aims to enhance the localized delivery and efficacy of established chemotherapeutic agents while reducing systemic toxicity. Its lead programs target hard-to-treat head and neck cancers, where improved tumor control and patient tolerability remain significant unmet needs.

The company’s pipeline comprises investigational product candidates in early and mid-stage clinical trials, including studies that combine its electrochemotherapy platform with radiation therapy and immuno-oncology agents.